185 related articles for article (PubMed ID: 22807165)
1. FDA approves first drug to prevent HIV infection.
Roehr B
BMJ; 2012 Jul; 345():e4879. PubMed ID: 22807165
[No Abstract] [Full Text] [Related]
2. AIDS research. FDA panel recommends anti-HIV drug for prevention.
Cohen J
Science; 2012 May; 336(6083):792. PubMed ID: 22605725
[No Abstract] [Full Text] [Related]
3. HIV pre-exposure prophylaxis.
Morin SF; Yamey G; Rutherford GW
BMJ; 2012 Aug; 345():e5412. PubMed ID: 22890030
[No Abstract] [Full Text] [Related]
4. Generic Truvada approved.
AIDS Patient Care STDS; 2009 May; 23(5):395. PubMed ID: 19422066
[No Abstract] [Full Text] [Related]
5. Transmission. Company halts Truvada PrEP for women study.
AIDS Policy Law; 2011 Jun; 26(7):1. PubMed ID: 21735622
[No Abstract] [Full Text] [Related]
6. FDA approves Viread for HIV-1 infection.
FDA Consum; 2002; 36(1):5. PubMed ID: 11881601
[No Abstract] [Full Text] [Related]
7. Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.
Blackwell CW
Nurse Pract; 2014 Sep; 39(9):50-3. PubMed ID: 25140852
[TBL] [Abstract][Full Text] [Related]
8. FDA PrEPares to reduce risk of HIV infection with Truvada®.
Breeze S
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):499. PubMed ID: 23272332
[No Abstract] [Full Text] [Related]
9. FDA approves two combo brand-name AIDS drugs.
Med Health; 2004 Aug; 58(31):3-4. PubMed ID: 15368717
[No Abstract] [Full Text] [Related]
10. Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.
Coutinho B; Prasad R
Am Fam Physician; 2013 Oct; 88(8):535-40. PubMed ID: 24364575
[No Abstract] [Full Text] [Related]
11. HIV prevention trial in women is abandoned after drugs show no impact on infection rates.
Roehr B
BMJ; 2011 Apr; 342():d2613. PubMed ID: 21508055
[No Abstract] [Full Text] [Related]
12. Mexico conference considers pre-exposure prophylaxis for AIDS.
Roehr B
BMJ; 2008 Aug; 337():a1278. PubMed ID: 18703652
[No Abstract] [Full Text] [Related]
13. Early end for FEM-PrEP HIV prevention trial.
AIDS Patient Care STDS; 2011 Jun; 25(6):383. PubMed ID: 21612547
[No Abstract] [Full Text] [Related]
14. HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.
Cohen J
Science; 2010 Dec; 330(6009):1298-9. PubMed ID: 21127220
[No Abstract] [Full Text] [Related]
15. Viread gets FDA nod.
Rodriquez E
Posit Living; 2001 Dec-2002 Jan; 10(7):33. PubMed ID: 11808509
[No Abstract] [Full Text] [Related]
16. [New fixed combination for HIV therapy].
Krankenpfl J; 2005; 43(4-6):95. PubMed ID: 16171046
[No Abstract] [Full Text] [Related]
17. FDA must publish data on safety and efficacy of prophylactic AIDS drug, court rules.
Hawkes N
BMJ; 2013 Aug; 347():f5161. PubMed ID: 23959292
[No Abstract] [Full Text] [Related]
18. HIV drug-prevention strategy carries risks.
Hayden EC
Nature; 2011 Aug; 476(7360):260-1. PubMed ID: 21850077
[No Abstract] [Full Text] [Related]
19. More pre-exposure prophylaxis for rising HIV infection?
Barreiro P
AIDS Rev; 2014; 16(2):118-9. PubMed ID: 24984768
[No Abstract] [Full Text] [Related]
20. Two-once-daily fixed-dose NRTI combinations for HIV.
Med Lett Drugs Ther; 2005 Feb; 47(1203):19-20. PubMed ID: 15767973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
